Article | Published:

Structure of the human histamine H1 receptor complex with doxepin

Nature volume 475, pages 6570 (07 July 2011) | Download Citation

Abstract

The biogenic amine histamine is an important pharmacological mediator involved in pathophysiological processes such as allergies and inflammations. Histamine H1 receptor (H1R) antagonists are very effective drugs alleviating the symptoms of allergic reactions. Here we show the crystal structure of the H1R complex with doxepin, a first-generation H1R antagonist. Doxepin sits deep in the ligand-binding pocket and directly interacts with Trp 4286.48, a highly conserved key residue in G-protein-coupled-receptor activation. This well-conserved pocket with mostly hydrophobic nature contributes to the low selectivity of the first-generation compounds. The pocket is associated with an anion-binding region occupied by a phosphate ion. Docking of various second-generation H1R antagonists reveals that the unique carboxyl group present in this class of compounds interacts with Lys 1915.39 and/or Lys 179ECL2, both of which form part of the anion-binding region. This region is not conserved in other aminergic receptors, demonstrating how minor differences in receptors lead to pronounced selectivity differences with small molecules. Our study sheds light on the molecular basis of H1R antagonist specificity against H1R.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Protein Data Bank

Data deposits

The coordinates and the structure factors have been deposited in the Protein Data Bank under the accession code 3RZE.

References

  1. 1.

    , , , & Histaminergic transmission in the mammalian brain. Physiol. Rev. 71, 1–51 (1991)

  2. 2.

    Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 42, 45–83 (1990)

  3. 3.

    et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49, 253–278 (1997)

  4. 4.

    et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc. Natl Acad. Sci. USA 88, 11515–11519 (1991)

  5. 5.

    Advances in H1-antihistamines. N. Engl. J. Med. 351, 2203–2217 (2004)

  6. 6.

    , & How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006)

  7. 7.

    , , & Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur. J. Pharmacol. 387, R5–R7 (2000)

  8. 8.

    , , , & Histamine H1-receptor activation of nuclear factor-κB: roles for Gβγ- and Gαq/11-subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 60, 1133–1142 (2001)

  9. 9.

    et al. Dose dependency of brain histamine H1 receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin. Hum. Psychopharmacol. 24, 540–548 (2009)

  10. 10.

    , , & Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc. 269, 1532–1536 (1993)

  11. 11.

    & Potential cardiac toxicity of H1-antihistamines. Clin. Allergy Immunol. 17, 389–419 (2002)

  12. 12.

    et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br. J. Pharmacol. 129, 115–123 (2000)

  13. 13.

    , & Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl.) 114, 559–565 (1994)

  14. 14.

    et al. The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol. Pharmacol. 78, 1026–1035 (2010)

  15. 15.

    & Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 3, 928–944 (2002)

  16. 16.

    , & Protein-coupled receptor models for structure-based virtual screening. Curr. Pharm. Des. 15, 4026–4048 (2009)

  17. 17.

    et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739–745 (2000)

  18. 18.

    et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318, 1258–1265 (2007)

  19. 19.

    et al. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454, 486–491 (2008)

  20. 20.

    et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211–1217 (2008)

  21. 21.

    & Crystal structure of squid rhodopsin. Nature 453, 363–367 (2008)

  22. 22.

    et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066–1071 (2010)

  23. 23.

    et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091–1095 (2010)

  24. 24.

    et al. Structure-based discovery of β2-adrenergic receptor ligands. Proc. Natl Acad. Sci. USA 106, 6843–6848 (2009)

  25. 25.

    et al. Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists. J. Med. Chem. 53, 1799–1809 (2010)

  26. 26.

    et al. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318, 1266–1273 (2007)

  27. 27.

    et al. Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur. J. Biochem. 271, 2636–2646 (2004)

  28. 28.

    & Integrated methods for the construction of three-dimensional models and computational probing of structure–function relations in G protein-coupled receptors. Methods Neurosci. 25, 366–428 (1995)

  29. 29.

    & Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol. Ther. 97, 1–33 (2003)

  30. 30.

    et al. Mutational analysis of the antagonist-binding site of the histamine H1 receptor. J. Biol. Chem. 274, 29994–30000 (1999)

  31. 31.

    et al. Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. Biochem. Biophys. Res. Commun. 203, 1096–1101 (1994)

  32. 32.

    et al. Unique binding pocket for KW-4679 in the histamine H1 receptor. Eur. J. Pharmacol. 345, 111–117 (1998)

  33. 33.

    et al. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens. Eur. J. Pharmacol. 487, 55–63 (2004)

  34. 34.

    , , & Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol. Sci. 32, 35–42 (2011)

  35. 35.

    et al. H1 antagonists: receptor affinity versus selectivity. Inflamm. Res. 52 (Suppl. 1). S49–S50 (2003)

  36. 36.

    , & Homology modelling and binding site mapping of the human histamine H1 receptor. Eur. J. Med. Chem. 39, 959–967 (2004)

  37. 37.

    & Delineation of receptor–ligand interactions at the human histamine H1 receptor by a combined approach of site-directed mutagenesis and computational techniques—or—how to bind the H1 receptor. Arch. Pharm. (Weinheim) 338, 248–259 (2005)

  38. 38.

    & Flexible protein–ligand docking by global energy optimization in internal coordinates. Proteins (Suppl. 1). 29, 215–220 (1997)

  39. 39.

    et al. Analysis of full and partial agonists binding to β2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J. Mol. Recognit. 22, 307–318 (2009)

  40. 40.

    , & Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacology 60, 108–115 (2011)

  41. 41.

    , , , & The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism. Pharmacology 81, 266–274 (2008)

  42. 42.

    , , , & Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194. Mol. Pharmacol. 61, 391–399 (2002)

  43. 43.

    , , , & Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. Biochem. Biophys. Res. Commun. 214, 110–117 (1995)

  44. 44.

    et al. 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol. Pharmacol. 65, 538–549 (2004)

  45. 45.

    et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322–327 (2011)

  46. 46.

    et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011)

  47. 47.

    , , , & High-throughput fluorescent-based optimization of eukaryotic membrane protein overexpression and purification in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 104, 13936–13941 (2007)

  48. 48.

    , , , & A robotic system for crystallizing membrane and soluble proteins in lipidic mesophases. Acta Crystallogr. D 60, 1795–1807 (2004)

  49. 49.

    et al. High-speed crystal detection and characterization using a fast-readout detector. Acta Crystallogr. D 66, 1032–1035 (2010)

  50. 50.

    xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Cryst. 43, 186–190 (2010)

  51. 51.

    Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 ESF-EACMB Newslet. Protein Crystallogr. No. 26. (1992)

  52. 52.

    Scaling and assessment of data quality. Acta Crystallogr. D 62, 72–82 (2006)

  53. 53.

    et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658–674 (2007)

  54. 54.

    , & Direct incorporation of experimental phase information in model refinement. Acta Crystallogr. D 60, 2196–2201 (2004)

  55. 55.

    , & Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240–255 (1997)

  56. 56.

    , , & Features and Development of Coot. Acta Crystallogr. D 66, 486–501 (2010)

  57. 57.

    , , & ICM Manual v.3.0 (MolSoft LLC, 2011)

  58. 58.

    & Derivation of sensitive discrimination potential for virtual ligand screening. Proceedings of the third annual international conference on computational molecular biology 312–317. (1999)

  59. 59.

    & Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235, 983–1002 (1994)

Download references

Acknowledgements

This work was supported by the ERATO Human Receptor Crystallography Project from the Japan Science and Technology Agency and by the Targeted Proteins Research Program of MEXT (S.I.), Japan; the NIH Common Fund grant P50 GM073197 for technology development (R.C.S.) and NIH PSI:Biology grant U54 GM094618 (R.C.S., V.C., V.K. and R.A.); R.A. was also partly funded by NIH R01 GM071872. The work was also partly funded by the Biotechnology and Biological Sciences Research Council (BBSRC) BB/G023425/1 (S.I.), Grant-in-Aid for challenging Exploratory Research (T.S.), the Mochida Memorial Foundation for Medical and Pharmaceutical Research (T.S. and T.K.), Takeda Scientific Foundation (M.S.) and the Sumitomo Foundation (T.K.). A part of the work was performed in the Membrane Protein Laboratory funded by the Wellcome Trust (grant 062164/ Z/00/Z) at the Diamond Light Source Limited and at The Scripps Research Institute. We thank D. Axford, R. Owen and G. Evans for help with data collection at I24 of the Diamond Light Source Limited, H. Wu for help with the preparation of Supplementary Fig. 1 and Q. Xu for help on validation of data processing and A. Walker for assistance with manuscript preparation. The authors acknowledge Y. Zheng (The Ohio State University) and M. Caffrey, Trinity College (Dublin, Ireland), for the loan of the in meso robot (built with support from the NIH (GM075915), the National Science Foundation (IIS0308078), and Science Foundation Ireland (02-IN1-B266)). S.I. is thankful for the help of L. E. Johnson, a co-founder of the Diamond-MPL Project and R. Tanaka, the technical coordinator of the ERATO Human Receptor Crystallography Project.

Author information

Author notes

    • Tatsuro Shimamura
    •  & Mitsunori Shiroishi

    These authors contributed equally to this work.

Affiliations

  1. Human Receptor Crystallography Project, ERATO, Japan Science and Technology Agency, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

    • Tatsuro Shimamura
    • , Mitsunori Shiroishi
    • , Simone Weyand
    • , Hirokazu Tsujimoto
    • , Takuya Kobayashi
    •  & So Iwata
  2. Department of Cell Biology, Graduate School of Medicine, Kyoto University, Yoshidakonoe-cho, Sakyo-Ku, Kyoto 606-8501, Japan

    • Tatsuro Shimamura
    • , Mitsunori Shiroishi
    • , Hirokazu Tsujimoto
    • , Takuya Kobayashi
    •  & So Iwata
  3. Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA

    • Tatsuro Shimamura
    • , Vadim Cherezov
    • , Wei Liu
    • , Gye Won Han
    •  & Raymond C. Stevens
  4. Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

    • Mitsunori Shiroishi
  5. Division of Molecular Biosciences, Membrane Protein Crystallography Group, Imperial College, London SW7 2AZ, UK

    • Simone Weyand
    •  & So Iwata
  6. Diamond Light Source, Harwell Science and Innovation Campus, Chilton, Didcot, Oxfordshire OX11 0DE, UK

    • Simone Weyand
    • , Graeme Winter
    •  & So Iwata
  7. Skaggs School of Pharmacy and Pharmaceutical Sciences and San Diego Supercomputer Center, University of California, San Diego, La Jolla, California 92093, USA

    • Vsevolod Katritch
    •  & Ruben Abagyan
  8. Systems and Structural Biology Center, RIKEN, 1-7-22 Suehiro-cho Tsurumi-ku, Yokohama 230-0045 Japan

    • So Iwata

Authors

  1. Search for Tatsuro Shimamura in:

  2. Search for Mitsunori Shiroishi in:

  3. Search for Simone Weyand in:

  4. Search for Hirokazu Tsujimoto in:

  5. Search for Graeme Winter in:

  6. Search for Vsevolod Katritch in:

  7. Search for Ruben Abagyan in:

  8. Search for Vadim Cherezov in:

  9. Search for Wei Liu in:

  10. Search for Gye Won Han in:

  11. Search for Takuya Kobayashi in:

  12. Search for Raymond C. Stevens in:

  13. Search for So Iwata in:

Contributions

T.S. purified and crystallized the receptor in LCP, optimized crystallization conditions, grew crystals for data collection, solved and refined the structure, and prepared the manuscript. M.S. designed, characterized and screened the constructs, purified the receptor, and prepared the manuscript. S.W. and S.I. collected the data and processed diffraction data with G.W.H. H.T. expressed the receptor, prepared the membrane, and performed the ligand-binding assay. V.K. and R.A. performed flexible ligand-receptor docking, and prepared the manuscript. V.C. assisted with the crystallization in LCP and prepared the manuscript. W.L. performed the thermal stability assay and assisted with the crystallization in LCP. G.W.H. refined the structure and assisted with preparing the manuscript. T.K. designed the receptor production strategy and assisted with preparing the manuscript. R.C.S. and S.I. were responsible for the overall project strategy and management and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Takuya Kobayashi or Raymond C. Stevens or So Iwata.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    The file contains Supplementary Tables 1-6, Supplementary Figures 1-5 with legends and an additional reference..

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature10236

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.